Name: Latest research reports of Mankind Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Mankind Pharma Ltd.

NSE: MANKIND | BSE: 543904 | ISIN: INE634S01028 | Industry: Pharmaceuticals
| Expensive Performer

2267.1000 10.10 (0.45%)

NSE Nov 14, 2025 15:31 PM

25.79% Fall from 52W High

Volume: 606.2K

Mankind Pharma Ltd.

01 Aug 2025

2267.10

0.45%

Cost headwinds lead to earnings miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) reported in-line revenue in 1QFY26. However, EBITDA/PAT came in 5%/7% below our estimates.

Mankind Pharma Ltd. has an average target of 2745.50 from 2 brokers.